Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study

被引：0
|
作者：
le Coutre, P.
Giles, F. J.
Apperley, J.
Ottmann, O. G.
Larson, R. A.
Haque, A.
Gallagher, N.
Rosti, G.
Cortes, J. E.
Kantarjian, H. M.
机构：
[1] Humboldt Univ, D-10099 Berlin, Germany
[2] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[3] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England
[4] Med Klin III, Frankfurt, Germany
[5] Univ Chicago Hosp, Chicago, IL 60637 USA
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Orsola Malpighi Univ, Bologna, Italy
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7050
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukaemia (CMC) in chronic phase (CP) or accelerated phase (AP)
    Cortes, J.
    Jabbour, E.
    Hochhaus, A.
    le Coutre, P.
    Baccarani, M.
    Bhalla, K. N.
    Ossenkoppele, G.
    Gattermann, N.
    Hague, A.
    Gallagher, N.
    Giles, F.
    Hill, S.
    Kantarjian, H. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 35 - 35
  • [22] Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study
    Kantarjian, H.
    Giles, F.
    Bhalla, K.
    Pinilla, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Gallagher, N. J.
    Baccarani, M.
    leCoutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Response and Outcomes to Nilotinib at 24 Months in Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) and Accelerated Phase (CML-AP) with and without BCR-ABL Mutations.
    Radich, Jerald P.
    Martinelli, Giovanni
    Hochhaus, Andreas
    Gottardi, Enrico
    Soverini, Simona
    Branford, Susan
    Mueller, Martin C.
    Beppu, Lan
    Shou, Yaping
    Haque, Ariful
    Woodman, Richard C.
    Kantarjian, Hagop M.
    Hughes, Timothy P.
    Kim, Dong-Wook
    Saglio, Giuseppe
    BLOOD, 2009, 114 (22) : 464 - 465
  • [24] Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results
    Kantarjian, H. M.
    Giles, F. J.
    Hochhaus, A.
    Bhalla, K. N.
    Ossenkoppele, G. J.
    Gattermann, N.
    Haque, A.
    Gallagher, N.
    Castagnetti, F.
    le Coutre, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Efficacy and Safety of Nilotinib in elderly patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance
    Ottmann, O. G.
    le Coutre, P.
    Gattermann, N.
    Hochhaus, A.
    Bruemmendorf, T. H.
    Kindler, T.
    Duyster, J.
    Al-Ali, H.
    Lipton, J.
    Wang, J.
    Yang, M.
    Szczudlo, T.
    Giles, F.
    ONKOLOGIE, 2010, 33 : 138 - 138
  • [26] Phase II study of decitabine in combination with imatinib mesylate in patients with accelerated (AP) or blastic phase (BP) of chronic myeloid leukemia (CML).
    Oki, Y
    Kantarjian, HM
    O'Brien, S
    Verstovsek, S
    Gharibyan, V
    Cortes, J
    Morris, GM
    Garcia-Manero, G
    Issa, JP
    BLOOD, 2005, 106 (11) : 320A - 320A
  • [27] Safety and Efficacy of Nilotinib (NIL) in Patients (Pts) with Chronic Phase (CP) or Accelerated Phase (AP) Philadelphia Chromosome Positive (Ph plus ) Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib Mesylate (IM): Results from the Multicenter, Observational NOVEL Study in Taiwan
    Kuo, Ching-Yuan
    Wang, Po-Nan
    Hwang, Wen Li
    Tzeng, Cheng-Hwai
    Bai, Li-Yuan
    Tang, Jih-Luh
    Chang, Ming-Chih
    Lin, Sheng-Fung
    Chen, Tsai-Yun
    Chen, Yeu-Chin
    Tran-Der Tan
    Hseih, Chih-Yi
    Lin, Chinjune
    Darko, Miljkovic
    Chang Cheng-Shyong
    BLOOD, 2015, 126 (23)
  • [28] A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant and -intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP).
    le Coutre, Philipp
    Bhalla, Kapil
    Giles, Francis
    Baccarani, Michele
    Ossenkoppele, Gert J.
    Hochhaus, Andreas
    Gattermann, Norbert
    Rafferty, Teresa
    Haque, Ariful
    Weitzman, Aaron
    Kantarjian, Hagop
    BLOOD, 2006, 108 (11) : 53A - 53A
  • [29] Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis
    Lipton, Jeffrey H.
    le Coutre, Philipp D.
    Wang, Jim
    Yang, Mindy
    Szczudlo, Tomasz
    Giles, Francis
    BLOOD, 2008, 112 (11) : 1110 - 1110
  • [30] A phase II study of nilotinib,a noveltyrosine kinase inhibitor administered to imatinib-resistant or -intolerant patients with philadelphiapositive chronic myelogenous leukemia in accelerated phase
    Le Coutre, P.
    Larson, R.
    Kantarjian, H.
    Gattermann, N.
    Hochhaus, A.
    Haque, A.
    Resta, D.
    Weitzman, A.
    Giles, F.
    O'Brien, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 207 - 208
12345